DMG-pSar25
Based on 1 Customer Validation
DMG-pSar25 is a double lipid-tailed polysarcosine lipid with 25 sarcosine moieties, serving as a PEG lipid substitute in lipid nanoparticle formulations for mRNA delivery. DMG-pSar25 supports mRNA delivery in lipid nanoparticle formulations.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99%
- CAS 番号: 2936622-30-7
- 分子量:2416.93
-
保管条件:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
DMG-pSar25 (50 ng firefly luciferase mRNA per well; 18 h) enhances mRNA delivery efficiency in ALC-0315 (HY-138300)-based LNPs in C2C12 and Hep3B cells compared to ALC-0159 PEG controls, while maintaining comparable cell viability[1].
DMG-pSar25 (50 ng firefly luciferase mRNA per well; 18 h) maintains mRNA delivery efficiency in SM-102 (HY-134541)-based LNPs in C2C12 and Hep3B cells compared to DMG-PEG2000 controls, while maintaining comparable cell viability[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice[1]
-
Dosage:0.06 µg mRNA
-
Administration:i.m.; single administration
-
Result:Produced greater than 5-fold higher total flux (luminescence intensity) than ALC-0315-based LNPs formulated with ALC-0159 PEG lipid.
Resulted in significantly higher hEPO levels in muscle (P = 0.008) compared to ALC-0315-based LNPs with ALC-0159 PEG lipid; hEPO levels in blood were similar between the two groups.
Showed comparable total flux and hEPO levels (blood and muscle) to SM-102-based LNPs formulated with DMG-PEG2000.
Exhibited cytokine/chemokine profiles largely similar to PEG-formulated LNPs, with SM-102-based DMG-pSar25 LNPs showing significantly higher levels of G-CSF (P = 0.005), IL-6 (P = 0.0003), CXCL10 (P = 0.04), CXCL1 (P = 0.0008), M-CSF (P = 0.01), CXCL9 (P = 0.04), and CCL4 (P = 0.02) compared to SM-102-based DMG-PEG2000 LNPs; ALC-0315-based DMG-pSar25 LNPs showing significantly higher levels of IFNγ (P = 0.02), IL-6 (P = 0.008), IL-4 (P = 0.04), and IL-5 (P = 0.02), and significantly lower IL-2 (P = 0.04) compared to ALC-0315-based ALC-0159 LNPs.
Did not induce anti-PEG IgG production upon repeat administration, whereas repeat administration of PEG-formulated LNPs did (P = 0.04).
Did not cause significant elevation of plasma aspartate transaminase (AST) and alanine transaminase (ALT) levels compared to PBS-treated mice.
化学情報
-
CAS 番号 2936622-30-7
-
性状 Solid
-
分子量 2416.93
-
Color White to off-white
-
SMILES
CN(C(CCC(OC[C@]([H])(OC(CCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCC)=O)=O)=O)C(CNCC)=O.[n]
-
Structure Classification
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
Ethanol : ≥ 50 mg/mL (20.69 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (268 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol | 1 mM | 0.4137 mL | 2.0687 mL | 4.1375 mL | 10.3437 mL |
| 5 mM | 0.0827 mL | 0.4137 mL | 0.8275 mL | 2.0687 mL | |
| 10 mM | 0.0414 mL | 0.2069 mL | 0.4137 mL | 1.0344 mL | |
| 15 mM | 0.0276 mL | 0.1379 mL | 0.2758 mL | 0.6896 mL | |
| 20 mM | 0.0207 mL | 0.1034 mL | 0.2069 mL | 0.5172 mL |
DMG-pSar25 関連分類
HY-N16040 関連分類
Powered by Bioz